Sign in
CompletedPhase 2

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Key facts

Who runs it
Sparrow Pharmaceuticals
Where
Germany and Poland9 sites in 2 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
66 people enrolled
Started
22 Jul 2022
Ended
25 Apr 2025
Type of study
Interventional, 2 groups
Treatments tested
  • SPI-62
  • SPI-62 matched placebo
  • Prednisolone 10mg
  • Additional prednisolone
  • Additional prednisolone matched placebo
Record updated
11 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Written informed consent
  • Diagnosis of PMR according to EULAR/ACR classification criteria
  • Absence of PMR relapse based on symptoms and acute phase markers
  • Daily oral prednisolone 10mg dose that will have been stable for at least 1-week at the Baseline visit and is expected to remain stable during the treatment period

Who cannot take part

  • Use of medications for treatment of PMR within specified intervals prior to the Baseline Visit other than oral prednisolone
  • Use of other medications likely to interfere with trial assessments
  • Any current or prior medical condition, medical or surgical therapies, or clinical trial participation expected to interfere with the conduct of the trial or the evaluation of its results
  • Any autoimmune disease (e.g., late-onset rheumatoid arthritis) other than PMR
  • Any contraindication for prednisolone administration
  • A diagnosis or any clinical features of giant cell arteritis
  • History or diagnosis of endogenous hypercortisolism

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in participants with PMR.

The 2 groups in the trial

  • SPI-62Treatment being tested

    Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.

    Treatment: SPI-62, SPI-62 matched placebo, and Prednisolone 10mg

  • SPI-62 + additional prednisoloneTreatment being tested

    Active drug / placebo by mouth each morning for up to 4 weeks + standard of care 10mg prednisolone + additional prednisolone or placebo. Each participant will receive both placebo and active drug but will be blinded to the sequence of active drug and placebo.

    Treatment: SPI-62, SPI-62 matched placebo, Prednisolone 10mg, Additional prednisolone, and Additional prednisolone matched placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
11 May 2025